Pharma News

Roche has announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of stage III deficient mismatch repair (dMMR) colon cancer.

The government has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines, aiming to reduce medicine prices by up to 70% and provide annual savings of ₹2,500 crore to cancer patients.

Halozyme Therapeutics is strengthening its position in subcutaneous drug delivery through two developments announced within a day of each other : a Dutch court ruling that restricts Merck’s Keytruda SC activities across multiple European markets.

The U.S. Food and Drug Administration (FDA) has approved Novartis’ Rhapsido® (remibrutinib) for adults with symptomatic dermographism (SD) whose symptoms are not adequately controlled with H1 antihistamines, making it the first FDA-approved treatment specifically for the condition.

Nova Biomedical has initiated a global medical device correction for its StatStrip Glucose Hospital Meter System after identifying a software issue that could cause a glucose test result to be associated with the wrong patient's medical record. The U.S. Food and Drug Administration (FDA) published the company's safety announcement on October 6, 2026.

A team from Flinders University’s Biomedical Nanoengineering Laboratory has found that vanillin has pronounced antioxidant, anti-inflammatory and antibacterial properties, making it a good candidate for wound-healing formulations.